Prior qualitative research has noted that gender dysphoria impacts sexual engagement and satisfaction for many trans masculine and nonbinary individuals. As such, the current cross-sectional study aimed to investigate the exact relations between distinct aspects of gender dysphoria (i.e., genital, chest, other secondary sex characteristics, and social) and engagement in, and enjoyment of, specific sexual acts. To achieve this aim, a sample of 141 trans masculine and nonbinary participants who were assigned female at birth and whom had not undertaken a medical transition were recruited. Participants were identified as trans masculine (n = 52), nonbinary (n = 72), and agender (n = 17). Participants completed a survey rating both body and social gender dysphoria and their engagement and enjoyment of receptive and performative roles across six partnered sex act domains (i.e., insertion, oral sex, sex toys, manual stimulation, nipple stimulation, and anal stimulation), as well as masturbation and noncoital activities. The overall results demonstrated that gender dysphoria is more salient to sexual acts that involve receiving versus providing sexual pleasure. In addition, genital and chest dysphoria were often significantly related to lower ratings of engagement and enjoyment. These results support the understanding that trans masculine and nonbinary individuals are likely negotiating sexual encounters to avoid sexual acts that involve areas of their body they find most distressing and marks an important area for future interventions and research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10508-021-02242-y | DOI Listing |
J Sex Marital Ther
January 2025
Department of Interdisciplinary Studies, University of South Florida, Tampa, FL, USA.
This paper critically examines the scientific and ethical underpinnings of gender-affirming care, particularly for minors. While major medical organizations endorse such interventions as medically necessary, the evidence supporting their long-term safety and efficacy remains limited. Research into hormonal, neuroanatomic, and genetic influences reveals a strong biological basis for gender identity, challenging social constructionist arguments.
View Article and Find Full Text PDFJCEM Case Rep
February 2025
Pediatric Endocrinology, Diabetology and Metabolism, Bern University Hospital, 3010 Bern, Switzerland.
3β-Hydroxysteroid dehydrogenase 2 deficiency (3βHSD2D) is a rare form of congenital adrenal hyperplasia (CAH) with variable clinical presentation. We describe a 46, XY child with ambiguous genitalia and CAH without apparent adrenal insufficiency due to 2 novel heterozygous variants in the gene (c.779C > T/p.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
Department of Biomedical Sciences, Rocky Vista University, Ivins, UT, United States.
[This corrects the article DOI: 10.3389/fendo.2023.
View Article and Find Full Text PDFInt J Gynaecol Obstet
January 2025
Endocrinology Division-Department of Medicine, University of Puerto Rico, San Juan, Puerto Rico, USA.
There is limited research concerning the transgender population's health issues, such as gender dysphoria, and disparities within the healthcare system, especially in the Latino or Hispanic population. This study aimed to report the case of a Puerto Rican transgender man who achieved pregnancy without reproductive assistance after cessation of testosterone therapy for 3 months and who in the postpartum period experienced significant gender dysphoria. A narrative literature review was carried out to identify the role of gender dysphoria in pregnancy, lactation, health-related spaces, and mental health.
View Article and Find Full Text PDFJ Adolesc Health
January 2025
Department of Endocrinology, Boston Children's Hospital, Boston, Massachusetts; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
Purpose: To understand the rate of, and reasons for, discontinuation of gender-affirming hormones (GAH) in transgender adolescents.
Methods: Retrospective cohort study of individuals starting GAH between January 2007 and December 2022. Individuals were included if they were diagnosed with gender dysphoria, were prescribed GAH, and took GAH continuously for a minimum of 6 months.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!